Model of CE of remdesivir for Covid-19_27Aug20.xlsx (971.01 kB)

MOSAIC: A model to assess the cost-effectiveness of remdesivir for admitted COVID-19 patients in South Africa

Download (971.01 kB)
MODEL STRATEGIES
This model assesses costs and outcomes for admitted severe and critical Covid-19 patients from time of admission to discharge or death
Four competing strategies are modelled:
1. The "status quo" summarizes costs and outcomes for patients assuming no dexamethasone or remdesivir
2. The "dexamethasone" comparator summarizes costs and outcomes for patients assuming dexamethasone at 6mg/day
3. The "remdesivir" comparator summarizes costs and outcomes for patients assuming remdesivir at 100mg/day
4. The "remdesivr plus dexamethasone" comparator summarizes costs and outcomes for patients assuming remdesivir at 100mg/day plus dexamethasone at 6mg/day
MODEL OUTCOMES
Cost: mean cost (general ward, ICU, dexamethasone and remdesivir as appropriate) per admitted patient from the health care provider's perspective
Health outcomes: mean DALYs and deaths per admitted patient
Other outcomes: mean ICU days and inpatient days per admitted patient
Budget impact: mean costs (or savings) associated with intervention implementation

History

Department/Unit

Health Economics Unit, School of Public Health and Family Medicine, University of Cape Town & Health Systems Research Unit, South African Medical Research Council

Licence

Exports

Logo branding

Licence

Exports